A Primer to Angiotensin Peptide Isolation, Stability, and Analysis by Nano-Liquid Chromatography with Mass Detection

  • Mariola OlkowiczEmail author
  • Stefan Chlopicki
  • Ryszard T. Smolenski
Part of the Methods in Molecular Biology book series (MIMB, volume 1614)


The renin-angiotensin system (RAS) is an important element of cardiovascular and renal physiology and targeting the RAS by renin inhibitors, angiotensin (Ang) converting enzyme (ACE) inhibitors and Ang II type 1 receptor antagonists is effective in the treatment of hypertension, heart failure, and atherosclerosis. Quantification of Ang peptides is critical to establish the status of the RAS, but it is challenging due to low Ang peptides concentrations (fmol/mL or fmol/g), abundance of interfering substances, post sampling conversions, and difficulties with the specificity of the assay.

In this chapter, we describe a new nano-LC/MS-based methodology for comprehensive, specific, sensitive, and accurate quantification of Ang peptides profile in plasma and tissue. We optimized sample pretreatment method (protein removal (acetonitrile precipitation) followed by solid-phase extraction (C18 silica bonded phase)), chromatographic conditions (reversed-phase nanochromatography with preconcentration), and mass detection (multiple reaction monitoring) of nine peptides: Ang-(1–12), Ang I (1–10), Ang-(1–9), Ang II (1–8), [Ala1]-Ang II, Ang III (2–8), Ang IV (3–8), Ang-(1–7), and [Ala1]-Ang-(1–7). Assessment of plasma and cardiac concentrations of Ang peptides in genetically modified atherosclerotic apolipoprotein E/LDL receptor double knockout (ApoE−/−/LDLR−/−) mice vs. wild types revealed changes in renin-angiotensin system consistent with an overactivation of ACE and impairment of ACE2. The method could be easily adopted for high-throughput analysis and for use in clinical applications such as diagnosis of the RAS abnormalities or monitoring of the RAS inhibition-based therapies.

Key words

Renin-angiotensin system Angiotensin peptides Sample handling and extraction Nanoflow liquid chromatography Multiple reaction monitoring Angiotensin concentrations in plasma and tissues 



This work was supported by the European Union from the resources of the European Regional Development Fund under the Innovative Economy Programme (a grant coordinated by JCET-UJ, No. POIG.01.01.02-00-069/09) and TEAM programme of the Foundation for Polish Science (TEAM/2011-8/7).


  1. 1.
    Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82–C97CrossRefPubMedGoogle Scholar
  2. 2.
    Balakumar P, Jagadeesh G (2014) A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cell Signal 26:2147–2160CrossRefPubMedGoogle Scholar
  3. 3.
    Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH (2015) Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 116:960–975CrossRefGoogle Scholar
  4. 4.
    Oparil S, Schmieder RE (2015) New approaches in the treatment of hypertension. Circ Res 116:1074–1095CrossRefPubMedGoogle Scholar
  5. 5.
    Passos-Silva DG, Brandan E, Santos RA (2015) Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol Sci 36:310–320CrossRefPubMedGoogle Scholar
  6. 6.
    Donoghue M, Hsieh F, Baronas E et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:E1–E9CrossRefPubMedGoogle Scholar
  7. 7.
    Keidar S, Kaplan M, Gamliel-Lazarovich A (2007) ACE2 of the heart: from angiotensin I to angiotensin (1–7). Cardiovasc Res 73:463–469CrossRefPubMedGoogle Scholar
  8. 8.
    McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA (2014) Angiotensin-(1–7) and angiotensin-(1–9): function in cardiac and vascular remodelling. Clin Sci (Lond) 126:815–827CrossRefGoogle Scholar
  9. 9.
    Jiang F, Yang J, Zhang Y et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol 11:413–426CrossRefPubMedGoogle Scholar
  10. 10.
    Jankowski V, Vanholder R, van der Giet M et al (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27:297–302CrossRefPubMedGoogle Scholar
  11. 11.
    Lautner RQ, Villela DC, Fraga-Silva RA et al (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112:1104–1111CrossRefPubMedGoogle Scholar
  12. 12.
    Etelvino GM, Peluso AA, Santos RA (2014) New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D. Curr Hypertens Rep 16:433CrossRefPubMedGoogle Scholar
  13. 13.
    Ferrario CM (2010) New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 55:445–452CrossRefPubMedGoogle Scholar
  14. 14.
    Allred AJ, Chappell MC, Ferrario CM, Diz DI (2000) Differential actions of renal ischemic injury on the intrarenal angiotensin system. Am J Physiol Renal Physiol 279:F636–F645PubMedGoogle Scholar
  15. 15.
    Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J (2000) Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35:985–991CrossRefPubMedGoogle Scholar
  16. 16.
    Nussberger J, Brunner DB, Nyfeler JA, Linder L, Brunner HR (2001) Measurement of immunoreactive angiotensin-(1–7) heptapeptide in human blood. Clin Chem 47:726–729PubMedGoogle Scholar
  17. 17.
    Yamamoto K, Ohishi M, Katsuya T et al (2006) Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47:718–726CrossRefPubMedGoogle Scholar
  18. 18.
    Lortie M, Bark S, Blantz R, Hook V (2009) Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry. Anal Biochem 394:164–170CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Olkowicz M, Radulska A, Suraj J et al (2015) Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice. J Chromatogr A 1393:37–46CrossRefPubMedGoogle Scholar
  20. 20.
    Olkowicz M, Chlopicki S, Smolenski RT (2015) Perspectives for angiotensin profiling with liquid chromatography/mass spectrometry to evaluate ACE/ACE2 balance in endothelial dysfunction and vascular pathologies. Pharmacol Rep 67:778–785CrossRefPubMedGoogle Scholar
  21. 21.
    Nussberger J, Brunner DB, Waeber B, Brunner HR (1985) True versus immunoreactive angiotensin II in human plasma. Hypertension 7:I1–I7CrossRefPubMedGoogle Scholar
  22. 22.
    Chappell MC (2016) Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol 310:H137–H152CrossRefPubMedGoogle Scholar
  23. 23.
    Poglitsch M, Sturrock ED, Danser AH (2016) Letter to the editor: angiotensin quantification by mass spectrometry. Am J Physiol Heart Circ Physiol 310(33):H452–H453CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Mariola Olkowicz
    • 1
    • 2
    Email author
  • Stefan Chlopicki
    • 3
    • 4
  • Ryszard T. Smolenski
    • 1
  1. 1.Department of BiochemistryMedical University of GdanskGdanskPoland
  2. 2.Department of Biotechnology and Food MicrobiologyPoznan University of Life SciencesPoznanPoland
  3. 3.Jagiellonian Centre for Experimental Therapeutics (JCET)Jagiellonian UniversityKrakowPoland
  4. 4.Department of Experimental PharmacologyJagiellonian University Medical CollegeKrakowPoland

Personalised recommendations